Identification of key pathways and biomarkers in sorafenib‑resistant hepatocellular carcinoma using bioinformatics analysis
- Authors:
- Danping Huang
- Weiqu Yuan
- Hanmin Li
- Shaodong Li
- Zuanguang Chen
- Hongzhi Yang
-
Affiliations: Guangdong Key Laboratory of Liver Disease Research, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510000, P.R. China, Acupuncture Department, The Fourth Clinical Medical College of Guangzhou University Chinese Medicine, Shenzhen, Guangdong 518000, P.R. China, Hepatopathy Institution, Affiliated Hospital Hubei University Chinese Medicine, Wuhan, Hubei 430061, P.R. China, Pharmaceutical Analysis Department, School of Pharmaceutical Sciences, Sun Yat‑sen University, Guangzhou, Guangdong 510006, P.R. China - Published online on: July 9, 2018 https://doi.org/10.3892/etm.2018.6427
- Pages: 1850-1858
-
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
 |
|
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Le Grazie M, Biagini MR, Tarocchi M, Polvani S and Galli A: Chemotherapy for hepatocellular carcinoma: The present and the future. World J Hepatol. 9:907–920. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, Peix J, Cabellos L, Alsinet C, Torrecilla S, et al: Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut. 66:530–540. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J, Takayama T, Mazzaferro V, Chau GY, Yang J, Kudo M, Cai J, Poon RT, Han KH, Tak WY, et al: Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): A phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 16:1344–1354. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 64:1090–1098. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Chen J, Jin R, Zhao J, Liu J, Ying H, Yan H, Zhou S, Liang Y, Huang D, Liang X, et al: Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367:1–11. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nannini M, Pantaleo MA, Maleddu A, Astolfi A, Formica S and Biasco G: Gene expression profiling in colorectal cancer using microarray technologies: Results and perspectives. Cancer Treat Rev. 35:201–209. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, et al: A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: Microfibril-associated glycoprotein 2. Cancer Cell. 16:521–532. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kadioglu O, Saeed M, Kuete V, Greten HJ and Efferth T: Oridonin targets multiple drug-resistant tumor cells as determined by in silico and in vitro analyses. Front Pharmacol. 9:3552018. View Article : Google Scholar : PubMed/NCBI | |
|
Li L, Wang G, Li N, Yu H, Si J and Wang J: Identification of key genes and pathways associated with obesity in children. Exp Ther Med. 14:1065–1073. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Z, Zhou Y, Cao Y, Dinh TL, Wan J and Zhao M: Identification of candidate biomarkers and analysis of prognostic values in ovarian cancer by integrated bioinformatics analysis. Med Oncol. 33:1302016. View Article : Google Scholar : PubMed/NCBI | |
|
Liang B, Li C and Zhao J: Identification of key pathways and genes in colorectal cancer using bioinformatics analysis. Med Oncol. 33:1112016. View Article : Google Scholar : PubMed/NCBI | |
|
Bader GD and Hogue CW: An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 4:22003. View Article : Google Scholar : PubMed/NCBI | |
|
Carl-McGrath S, Lendeckel U, Ebert M and Röcken C: Ectopeptidases in tumor biology: A review. Histol Histopathol. 21:1339–1353. 2006.PubMed/NCBI | |
|
Cordero OJ, Ayude D, Nogueira M, Rodriguez-Berrocal FJ and de la Cadena MP: Preoperative serum CD26 levels: Diagnostic efficiency and predictive value for colorectal cancer. Br J Cancer. 83:1139–1146. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda N, Nakajima Y, Tokuhara T, Hattori N, Sho M, Kanehiro H and Miyake M: Clinical significance of aminopeptidase N/CD13 expression in human pancreatic carcinoma. Clin Cancer Res. 9:1503–1508. 2003.PubMed/NCBI | |
|
Murakami H, Yokoyama A, Kondo K, Nakanishi S, Kohno N and Miyake M: Circulating aminopeptidase N/CD13 is an independent prognostic factor in patients with non-small cell lung cancer. Clin Cancer Res. 11:8674–8679. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Larrinaga G, Blanco L, Sanz B, Perez I, Gil J, Unda M, Andrés L, Casis L and López JI: The impact of peptidase activity on clear cell renal cell carcinoma survival. Am J Physiol Renal Physiol. 303:F1584–F1591. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
McDonnell DP, Park S, Goulet MT, Jasper J, Wardell SE, Chang CY, Norris JD, Guyton JR and Nelson ER: Obesity, cholesterol metabolism, and breast cancer pathogenesis. Cancer Res. 74:4976–4982. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lin CY, Huo C, Kuo LK, Hiipakka RA, Jones RB, Lin HP, Hung Y, Su LC, Tseng JC, Kuo YY, et al: Cholestane-3β, 5α, 6β-triol suppresses proliferation, migration, and invasion of human prostate cancer cells. PLoS One. 8:e657342013. View Article : Google Scholar : PubMed/NCBI | |
|
Murtola TJ, Visvanathan K, Artama M, Vainio H and Pukkala E: Statin use and breast cancer survival: A nationwide cohort study from finland. PLoS One. 9:e1102312014. View Article : Google Scholar : PubMed/NCBI | |
|
Cardwell CR, Hicks BM, Hughes C and Murray LJ: Statin use after colorectal cancer diagnosis and survival: A population-based cohort study. J Clin Oncol. 32:3177–3183. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Jacobs EJ, Newton CC, Thun MJ and Gapstur SM: Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res. 71:1763–1771. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhuo H, Lyu Z, Su J, He J, Pei Y, Cheng X, Zhou N, Lu X, Zhou S and Zhao Y: Effect of lung squamous cell carcinoma tumor microenvironment on the CD105+ endothelial cell proteome. J Proteome Res. 13:4717–4729. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Han B, Nakamura M, Mori I, Nakamura Y and Kakudo K: Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 14:105–112. 2005.PubMed/NCBI | |
|
Tsunoda T, Nakamura T, Ishimoto K, Yamaue H, Tanimura H, Saijo N and Nishio K: Upregulated expression of angiogenesis genes and down regulation of cell cycle genes in human colorectal cancer tissue determined by cDNA macroarray. Anticancer Res. 21:137–143. 2001.PubMed/NCBI | |
|
Romero-Cordoba SL, Salido-Guadarrama I, Rodriguez-Dorantes M and Hidalgo-Miranda A: miRNA biogenesis: Biological impact in the development of cancer. Cancer Biol Ther. 15:1444–1455. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Perez R, Wu N, Klipfel AA and Beart RW Jr: A better cell cycle target for gene therapy of colorectal cancer: Cyclin G. J Gastrointest Surg. 7:884–889. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Tominaga O, Nita ME, Nagawa H, Fujii S, Tsuruo T and Muto T: Expressions of cell cycle regulators in human colorectal cancer cell lines. Jpn J Cancer Res. 88:855–860. 2003. View Article : Google Scholar | |
|
van den Berg YW, Osanto S, Reitsma PH and Versteeg HH: The relationship between tissue factor and cancer progression: Insights from bench and bedside. Blood. 119:924–932. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Pesson M, Volant A, Uguen A, Trillet K, De La Grange P, Aubry M, Daoulas M, Robaszkiewicz M, Le Gac G, Morel A, et al: A gene expression and pre-mRNA splicing signature that marks the adenoma-adenocarcinoma progression in colorectal cancer. PLoS One. 9:e877612014. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai TH, Song E, Zhu R, Di Poto C, Wang M, Luo Y, Varghese RS, Tadesse MG, Ziada DH, Desai CS, et al: LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics. 15:2369–2381. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, Izzo F, La Vecchia C, Boffetta P and Montella M: Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 108:222–228. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Baffy G, Brunt EM and Caldwell SH: Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace. J Hepatol. 56:1384–1391. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Boroughs LK and DeBerardinis RJ: Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 17:351–359. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang W, Huang H, Ding L, Zhu P, Saiyin H, Ji G, Zuo J, Han D, Pan Y, Ding D, et al: Regulation of cell cycle of hepatocellular carcinoma by NF90 through modulation of cyclin E1 mRNA stability. Oncogene. 34:4460–4470. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Clawson GA, Feldherr CM and Smuckler EA: Nucleocytoplasmic RNA transport. Mol Cell Biochem. 67:87–99. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Quesada-Calvo F, Massot C, Bertrand V, Longuespée R, Blétard N, Somja J, Mazzucchelli G, Smargiasso N, Baiwir D, De Pauw-Gillet MC, et al: OLFM4, KNG1 and Sec24C identified by proteomics and immunohistochemistry as potential markers of early colorectal cancer stages. Clin Proteomics. 14:92017. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Wang X, Lin S, Chen C, Wang C, Ma Q and Jiang B: Identification of kininogen-1 as a serum biomarker for the early detection of advanced colorectal adenoma and colorectal cancer. PLoS One. 8:e705192013. View Article : Google Scholar : PubMed/NCBI | |
|
Wahab Abdel AHA, El-Halawany MS, Emam AA, Elfiky A and Elmageed Abd ZY: Identification of circulating protein biomarkers in patients with hepatocellular carcinoma concomitantly infected with chronic hepatitis C virus. Biomarkers. 22:621–628. 2017.PubMed/NCBI | |
|
He X, Wang Y, Zhang W, Li H, Luo R, Zhou Y, Liao CL, Huang H, Lv X, Xie Z and He M: Screening differential expression of serum proteins in AFP-negative HBV-related hepatocellular carcinoma using iTRAQ -MALDI-MS/MS. Neoplasma. 61:17–26. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Wang C, Liu CM, Wei LL, Shi LY, Pan ZF, Mao LG, Wan XC, Ping ZP, Jiang TT, Chen ZL, et al: A group of novel serum diagnostic biomarkers for multidrug-resistant tuberculosis by iTRAQ-2D LC-MS/MS and solexa sequencing. Int J Biol Sci. 12:246–256. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Koch AE, Halloran MM, Haskell CJ, Shah MR and Polverini PJ: Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature. 376:517–519. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A and Bundred NJ: Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst. 92:1329–1336. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Yoong KF, McNab G, Hubscher SG and Adams DH: Vascular adhesion protein-1 and ICAM-1 support the adhesion of tumor-infiltrating lymphocytes to tumor endothelium in human hepatocellular carcinoma. J Immunol. 160:3978–3988. 1998.PubMed/NCBI | |
|
Alexiou D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I and Tsigris C: Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: Correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 37:2392–2397. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Kang X, Wang F, Xie JD, Cao J and Xian PZ: Clinical evaluation of serum concentrations of intercellular adhesion molecule-1 in patients with colorectal cancer. World J Gastroenterol. 11:4250–4253. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
O'Hanlon DM, Fitzsimons H, Lynch J, Tormey S, Malone C and Given HF: Soluble adhesion molecules (E-selectin, ICAM-1 and VCAM-1) in breast carcinoma. Eur J Cancer. 38:2252–2257. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ho JW, Poon RT, Tong CS and Fan ST: Clinical significance of serum vascular cell adhesion molecule-1 levels in patients with hepatocellular carcinoma. World J Gastroenterol. 10:2014–2018. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Iliaz R, Akyuz U, Tekin D, Serilmez M, Evirgen S, Cavus B, Soydinc H, Duranyildiz D, Karaca C, Demir K, et al: Role of several cytokines and adhesion molecules in the diagnosis and prediction of survival of hepatocellular carcinoma. Arab J Gastroenterol. 17:164–167. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz-Sanchez A, Matilla A, Nunez O, Rincon D, Lorente R, Iacono Lo O, Merino B, Hernando A, Campos R, Clemente G and Bañares R: Serum level of soluble vascular cell adhesion molecule in patients with hepatocellular carcinoma and its association with severity of liver disease. Ann Hepatol. 12:236–247. 2013.PubMed/NCBI | |
|
Scalici JM, Thomas S, Harrer C, Raines TA, Curran J, Atkins KA, Conaway MR, Duska L, Kelly KA and Slack-Davis JK: Imaging VCAM-1 as an indicator of treatment efficacy in metastatic ovarian cancer. J Nucl Med. 54:1883–1889. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Azrolan N, O'Connell A, Walsh A and Breslow JL: Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science. 249:790–793. 1990. View Article : Google Scholar : PubMed/NCBI | |
|
Chan AW, Wong GL, Chan HY, Tong JH, Yu YH, Choi PC, Chan HL, To KF and Wong VW: Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B. J Gastroenterol Hepatol. 32:667–676. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong DN, Ning QY, Wu JZ, Zang N, Wu JL, Hu DF, Luo SY, Huang AC, Li LL and Li GJ: Comparative proteomic profiles indicating genetic factors may involve in hepatocellular carcinoma familial aggregation. Cancer Sci. 103:1833–1838. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, et al: Fetuin A in nonalcoholic fatty liver disease: In vivo and in vitro studies. Eur J Endocrinol. 166:503–510. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E, Ozdogan O, Imeryuz N, et al: Serum fetuin A/α2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: Relation with liver fibrosis. Ann Clin Biochem. 47:549–553. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao ZW, Lin CG, Wu LZ, Luo YK, Fan L, Dong XF and Zheng H: Serum fetuin-A levels are associated with the presence and severity of coronary artery disease in patients with type 2 diabetes. Biomarkers. 18:160–164. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kaushik SV, Plaisance EP, Kim T, Huang EY, Mahurin AJ, Grandjean PW and Mathews ST: Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. Diabetes Metab Res Rev. 25:427–434. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kalabay L, Jakab L, Prohaszka Z, Füst G, Benkö Z, Telegdy L, Lörincz Z, Závodszky P, Arnaud P and Fekete B: Human fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell function and short-term mortality in patients with liver cirrhosis and liver cancer. Eur J Gastroenterol Hepatol. 14:389–394. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Guillory B, Sakwe AM, Saria M, Thompson P, Adhiambo C, Koumangoye R, Ballard B, Binhazim A, Cone C, Jahanen-Dechent W and Ochieng J: Lack of fetuin-A (alpha2-HS-glycoprotein) reduces mammary tumor incidence and prolongs tumor latency via the transforming growth factor-beta signaling pathway in a mouse model of breast cancer. Am J Pathol. 177:2635–2644. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Swallow CJ, Partridge EA, Macmillan JC, Tajirian T, DiGuglielmo GM, Hay K, Szweras M, Jahnen-Dechent W, Wrana JL, Redston M, et al: alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression. Cancer Res. 64:6402–6409. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Xiang Y, Liu Y, Yang Y, Hu H, Hu P, Ren H and Zhang D: A secretomic study on human hepatocellular carcinoma multiple drug-resistant cell lines. Oncol Rep. 34:1249–1260. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Hyung SW, Lee MY, Yu JH, Shin B, Jung HJ, Park JM, Han W, Lee KM, Moon HG, Zhang H, et al: A serum protein profile predictive of the resistance to neoadjuvant chemotherapy in advanced breast cancers. Mol Cell Proteomics. 10(M111): 0110232011.PubMed/NCBI | |
|
Kirschbaum MH and Yarden Y: The ErbB/HER family of receptor tyrosine kinases: A potential target for chemoprevention of epithelial neoplasms. J Cell Biochem Suppl. 34:52–60. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J and Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707–712. 1989. View Article : Google Scholar : PubMed/NCBI | |
|
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M and Akita R: Her-2/neu expression in node-negative breast cancer: Direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 53:4960–4970. 1993.PubMed/NCBI | |
|
Colak D, Chishti MA, Al-Bakheet AB, Al-Qahtani A, Shoukri MM, Goyns MH, Ozand PT, Quackenbush J, Park BH and Kaya N: Integrative and comparative genomics analysis of early hepatocellular carcinoma differentiated from liver regeneration in young and old. Mol Cancer. 9:1462010. View Article : Google Scholar : PubMed/NCBI | |
|
Nakopoulou L, Stefanaki K, Filaktopoulos D and Giannopoulou I: C-erb-B-2 oncoprotein and epidermal growth factor receptor in human hepatocellular carcinoma: An immunohistochemical study. Histol Histopathol. 9:677–682. 1994.PubMed/NCBI | |
|
Hamazaki K, Yunoki Y, Tagashira H, Mimura T, Mori M and Orita K: Epidermal growth factor receptor in human hepatocellular carcinoma. Cancer Detect Prev. 21:355–360. 1997.PubMed/NCBI | |
|
Prange W and Schirmacher P: Absence of therapeutically relevant c-erbB-2 expression in human hepatocellular carcinomas. Oncol Rep. 8:727–730. 2001.PubMed/NCBI | |
|
Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A and Grigioni WF: Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 35:332–338. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M and Matsuura N: Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 84:1377–1383. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S and Bardelli A: Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Discov. 4:1269–1280. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Vaz J, Ansari D, Sasor A and Andersson R: SPARC: A potential prognostic and therapeutic target in pancreatic cancer. Pancreas. 44:1024–1035. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Nagaraju GP, Dontula R, El-Rayes BF and Lakka SS: Molecular mechanisms underlying the divergent roles of SPARC in human carcinogenesis. Carcinogenesis. 35:967–973. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lau CP, Poon RT, Cheung ST, Yu WC and Fan ST: SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol. 210:459–468. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Massi D, Franchi A, Borgognoni L, Reali UM and Santucci M: Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol. 30:339–344. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Golembieski WA, Ge S, Nelson K, Mikkelsen T and Rempel SA: Increased SPARC expression promotes U87 glioblastoma invasion in vitro. Int J Dev Neurosci. 17:463–472. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Thomas R, True LD, Bassuk JA, Lange PH and Vessella RL: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res. 6:1140–1149. 2000.PubMed/NCBI | |
|
Wang T, Srivastava S, Hartman M, Buhari SA, Chan CW, Iau P, Khin LW, Wong A, Tan SH, Goh BC and Lee SC: High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. Oncotarget. 7:55155–55168. 2016.PubMed/NCBI | |
|
Seiffert D, Geisterfer M, Gauldie J, Young E and Podor TJ: IL-6 stimulates vitronectin gene expression in vivo. J Immunol. 155:3180–3185. 1995.PubMed/NCBI | |
|
Edwards S, Lalor PF, Tuncer C and Adams DH: Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br J Cancer. 95:1545–1554. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nejjari M, Hafdi Z, Gouyss G, Fiorentino M, Béatrix O, Dumortier J, Pourreyron C, Barozzi C, D'errico A, Grigioni WF and Scoazec JY: Expression, regulation, and function of alpha V integrins in hepatocellular carcinoma: An in vivo and in vitro study. Hepatology. 36:418–426. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Ferrin G, Ranchal I, Llamoza C, Rodríguez-Perálvarez ML, Romero-Ruiz A, Aguilar-Melero P, López-Cillero P, Briceño J, Muntané J, Montero-Álvarez JL and De la Mata M: Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 2-D DIGE. Liver Int. 34:438–446. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Ding Y and Shen Y: Notch increased vitronection adhesion protects myeloma cells from drug induced apoptosis. Biochem Biophys Res Commun. 467:717–722. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sun S, Poon RT, Lee NP, Yeung C, Chan KL, Ng IO, Day PJ and Luk JM: Proteomics of hepatocellular carcinoma: Serum vimentin as a surrogate marker for small tumors (<or=2 cm). J Proteome Res. 9:1923–1930. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Lazarova DL and Bordonaro M: Vimentin, colon cancer progression and resistance to butyrate and other HDACis. J Cell Mol Med. 20:989–993. 2016. View Article : Google Scholar : PubMed/NCBI |
